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Abstract Sensitive and robust bioassays for glucocorti-
coids are very useful for the pharmaceutical industry,
environmental scientists and veterinary control. Here, a
recombinant yeast cell was constructed that expresses the
human glucocorticoid receptor alpha and a green fluores-
cent reporter protein in response to glucocorticoids. Both
the receptor construct and the reporter construct were stably
integrated into the yeast genome. The correct and specific
functioning of this yeast glucocorticoid bioassay was
studied by exposures to cortisol and other related com-
pounds and critically compared to a GR-CALUX bioassay
based on a human bone cell. Although less sensitive, the
new yeast glucocorticoid bioassay showed sensitivity
towards all (gluco)corticoids tested, with the following
order in relative potencies: budesonide >> corticosterone >
dexamethasone > cortisol = betamethasone > prednisolone >
aldosterone. Hormone representatives for other hormone
nuclear receptors, like 17β-estradiol for the oestrogen
receptor, 5α-dihydrotestosterone for the androgen receptor
and progesterone for the progesterone receptor, showed no
clear agonistic responses, whilst some polychlorinated
biphenyls were clearly able to interfere with the GR activity.
Keywords Activity screening . Bioassay. Contaminants .
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Introduction
There is an overwhelming amount of evidence that certain
chemicals, also present in our environment, food and water,
can affect human health by disrupting the endocrine system,
possibly leading to adverse effects. Examples include
reproductive failure and tumour formation in sensitive
target tissues [1, 2]. Most attention has been paid to
compounds that are able to alter the activity of the human
oestrogen receptor (hER) or androgen receptor (hAR)
directly [3, 4]. Both the ER and AR belong to a large
superfamily of receptors, called nuclear receptors. This
class of receptors also includes the retinoic acid receptor,
vitamin D receptor, progesterone receptor (PR), thyroid
receptor, peroxisome proliferator-activated receptor, mineralo-
corticoid receptor (MR) and the glucocorticoid receptor (GR).
There are a lot of bioassays available for the oestrogens and
androgens and only a few for the other hormones. Oestrogens
and androgens draw a lot of attention because their congruent
receptors are involved in many diseases and because oestro-
gens and androgens are relatively very potent [5]. However,
although glucocorticoids are relatively less potent, they
are extremely interesting as, in contrast to the hER and
hAR that are mainly expressed in the sex organs, the
human glucocorticoid receptor (hGR) is expressed in
every cell type [6].
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The hGR is encoded by gene NR3C1 on chromosome 5
(5q31-32) [7–9] and is involved in the regulation of a wide
variety of processes, including development, metabolism,
bone density, and growth of cells and also affects the
cardiovascular system, the hypothalamic–pituitary–adrenal
axis, the immune response and behaviour [10–12]. The
hGR is present in two main isoforms, hGRα and hGRβ.
Both isoforms are largely identical, but the β-splice variant
misses helix 12 which is an essential part of the ligand-
binding domain (LBD). Only hGRα is therefore able to
bind ligands effectively and is subsequently capable of
binding and activating glucocorticoid-responsive elements
(GRE) on the DNA transcriptional level. The physiologic
importance of hGRβ on the other hand is still uncertain [9,
13–15]. In humans, the main corticoids are produced in
different parts of the adrenal glands. The glucocorticoid
cortisol is produced in the fasciculate and the mineralocor-
ticoid aldosterone in the glomerulosa, whilst DHEA
sulphate, which is a precursor for androgens and oestrogens,
is produced in the reticularis [16]. Altered cortisol production
can hamper the general metabolism, immune response and
stress resistance [17]. Aldosterone is involved in sodium/
potassium homeostasis, and strong inhibition of aldosterone
secretion will result in the salt-wasting characteristics of
Addison’s disease [18].
Glucocorticoids are potent pharmaceuticals, and although
their modes of action are not fully understood, they are
successfully used for the therapeutic treatment of patients
with a variety of disorders and diseases. The synthetic
glucocorticoid dexamethasone for instance is used for the
treatment of rheumatoid arthritis and is given to cancer
patients to counteract certain side effects of their
chemotherapy [19, 20]. In livestock production, glucocorti-
coids are administered because of their inhibition of
inflammatory, allergic and immunological responses, and as
such can be misused to mask bad nursing, housekeeping and
feeding of animals. Moreover, glucocorticoids are very
tempting for broilers as they also stimulate growth and
improve feed conversion [21–24]. Due to the potential health
effects, maximum residue limits for these compounds have
been established in milk and tissues intended for human
consumption, whilst the application of glucocorticoids as
growth promoters is banned in the European Union [25–27].
Polychlorinated biphenyls (PCBs) are widespread envi-
ronmental pollutants, and although their production and
commercialisation has been largely prohibited since the
1970s, their chemical stability, persistency and lipophilic
character resulted in their tendency to accumulate in the
food chain, environment, wildlife and humans. They can
be found in human samples such as blood serum, cord
blood and breast milk. PCB101 and its 3MeSO2
metabolite are among the most abundant PCBs present in
humans and wildlife [28].
Applicable bioassays for glucocorticoids are useful for
the pharmaceutical industry, i.e. to develop compounds with
specific agonistic and antagonistic properties; environmental
scientists, i.e. to characterise contaminants; and the veterinary
control, i.e. to detect the illegal use of corticosteroids. This
study describes the development of a yeast glucocorticoid
bioassay based on the constitutive expression of hGRα and a
green fluorescent reporter protein upon exposure to glucocor-
ticoids. The sensitivity and specificity of this bioassay was
determined by testing a range of natural and synthetic (gluco)
corticoids and several environmental PCB contaminants
known to affect the human endocrine system.
Materials and methods
Chemicals
Alosterone, betamethasone, budesonide, corticosterone,
cortisol, cortisone, 5α-dihydrotestosterone (5α-DHT),
dexamethasone (Dex), 17β-estradiol (E2), fludrocortisone-
21-acetate, mifepristone, prednisolone, prednisone, proges-
terone (P4) and triamcinolone were obtained from Sigma;
17β-testosterone (T) from Steraloids; and dimethyl sulfoxide
(DMSO) from Merck. Org 34116, Org 34517 and Org 34850
were kindly provided by Dr. Willem Schoonen from MSD
(Oss, the Netherlands); PCB47, PCB92, PCB100 and
PCB101 were provided by Dr. Majorie van Duursen from
IRAS (Utrecht, the Netherlands) who obtained these PCBs
from Neosync, Inc., USA. Possible impurities in these PCB
standards were removed by a cleanup over an active carbon
column. Chemicals to prepare the growth media and the
preparation of the growth media for both the yeast cells as the
U2-OS cell line were as described elsewhere [29, 30].
Plasmids
The p403-GPD-His yeast vector described by Mumberg et
al. [31] was used for the expression of the human
glucocorticoid receptor α. This plasmid contains the
HIS3 marker gene and the strong constitutive yeast
glyceraldehyde-3-phosphate dehydrogenase (GPD) promoter.
This plasmid was previously used to obtain high expression
levels of the hERα, hERβ and hAR in yeast [32, 33]. The
pCDNA3/hGRα plasmid containing the full-length cDNA of
the hGRα was a gift from Michael Garabedian (NYU).
Construction of the p403-GPD-hGRα expression vector
There were no suited restriction sites for the cut-and-paste
principle to get the full-length cDNA of the hGRα out of
the pCDNA3/hGRα plasmid and paste it behind the strong
GPD promoter of the p403-GPD-His vector. A full-length
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hGRα cDNA was therefore obtained by a PCR with
proofreading polymerases. The 5′-end primer contained a
Xba 1 restriction site before the ATG start codon and had
the following sequence: 5′-GCTCTAGAACTGATGGAC
TCCAAAG-3′. The sequence of the 3′-end primer was:
5′-GCGGATCCAGTCACTTTTGATGAAA-3′, containing
a restriction site for BamH 1 just after the TGA stop
codon. The 2,334-bp full-length hGRα PCR product was
isolated from a 1% low-melt agarose gel and was ligated
into the corresponding restriction sites of the p403-GPD-
His vector. This p403-GPD-hGRα-His vector was used to
transform Epicurian Coli XL-2 Blue Cells. Digestion and
PCR controls performed on isolated plasmids from single
white colonies revealed several good clones (data not
shown).
Transformation of yeast cells
Previously, a yeast K20 (Ura−, His−, Leu−) cell was
transformed with a p406-HRE2-CYC1-yEGFP-Ura reporter
construct and used to construct a yeast androgen bioassay
[33]. The hormone-responsive element (HRE) used in that
reporter plasmid is not only recognised by the hAR but can
also bind an activated hGRα complex. That previously
constructed HRE2-CYC1-yEGFP-Ura reporter yeast was
used here to construct the yeast glucocorticoid bioassay by
transforming it with the constructed p403-GPD-hGRα-His
vector. Transformation was performed with the lithium
acetate procedure as described previously [29]. In short, the
p403-GPD-hGRα-His vector was linearised by cutting with
Mcs I, which has a unique restriction site in the HIS3
marker gene (Histidine). Transformants were grown on
minimal medium containing leucine only (MM/L). Stable
transformants, i.e. with the receptor construct integrated in
the yeast genome at the chromosomal location of the
Histidine gene via homologous recombination, were
checked with PCR controls on isolated chromosomal
DNA. PCR I was performed with the primers that were
also used to obtain the full-length cDNA of the human
glucocorticoid receptor as described above and results in
a 2,334-bp full-length hGRα PCR product. PCR II was
performed with internal primers on the cDNA of the
human glucocorticoid receptor. The 5′-end primer had the
following sequence: 5′-CCCTGGTCGAACAGTTTTTT-
3′. The sequence of the 3′-end primer was: 5′-AGCG
TAGTCATGATCCTCCA-3′. This PCR control would
generate a 539-bp PCR product. PCR III was performed
with a 5′-end primer on the GPD promoter and a 3′-end
primer on the CYC1 terminator. The sequence of the 5′-
and 3′-end primers were 5′-CAGTTCCCTGAAATTAT
TCCCCTAC-3′ and 5′-GGGAGGGCGTGAATGTAAG-
3′, respectively, and would result in a 2,590-bp PCR
product.
The yeast glucocorticoid bioassay
Cultures of the yeast glucocorticoid biosensor were grown
overnight at 30 °C with vigorous orbital shaking in the
selective minimal medium supplemented with L-leucine
(MM/L). At the late log phase, the culture was diluted in
MM/L to an optical density (OD) value at 630 nm was
reached between 0.04 and 0.06. For exposure, aliquots of
200 μl of this diluted yeast culture were pipetted into each
well of a 96-well plate and 2 μl of a stock solution in
DMSO was added to test the agonistic properties of the
compounds. To test for anti-(gluco)corticoid properties, 1-
μl amounts of the stock solutions were co-exposed with
either 1 μl of budesonide or dexamethasone stock solutions
known to cause either a half-maximal or a near-maximal
response. DMSO and controls containing only budesonide
or dexamethasone were included in each experiment; each
sample concentration was assayed in triplicate. Exposure
was performed for 24 h at 30 °C and orbital shaking
(125 rpm). Fluorescence and OD were measured at 0 and
24 h directly in a SynergyTM HT Multi-Detection
Microplate Reader (BioTek Instruments Inc., USA) using
excitation at 485 nm and emission at 530 nm for the
fluorescent measurement. The fluorescent signal was
corrected with the signals obtained with the supple-
mented MM containing DMSO solvent only, whilst the
OD measurement at 630 nm was only performed to
check whether a sample was toxic for the yeast cells.
The U2-OS human bone cell line-based GR-CALUX
bioassay
The GR-CALUX cell line was obtained from BioDetection
Systems B.V. (Amsterdam, the Netherlands). This GR-
CALUX bioassay is based on human osteoblastic osteosar-
coma U2-OS cells (American Type Cell Culture) trans-
fected with a hGRα expression plasmid and a luciferase
reporter construct. The GR-CALUX bioassay is performed
as described before [30, 34]. In short, GR-CALUX cells
were cultured in DF medium supplemented with 7.5%
foetal calf serum (FCS) and 200 μg/ml G418. For exposure,
GR-CALUX cells were plated in 96-well plates with phenol
red-free DF medium supplemented with 5% dextran-coated
charcoal-stripped FCS (DCC-FCS) at a volume of 200 μl
per well. Two days later, the medium was refreshed and
cells were incubated with the compounds to be tested
dissolved in DMSO; each compound concentration was
analysed in triplicate (final DMSO concentration is
0.2%). After 24 h, the medium was removed, cells
were lysed in Triton lysis buffer, and luciferase activity
was measured using a Synergy HT Multi-Detection
Microplate Reader (luminometer of BioTek Instruments
Inc., USA).
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Results
For the development of specific bioassays, and especially in
the case of bioassays for glucocorticoids, progestagens and
androgens, the lack of endogenous receptors in yeast is a
great advantage compared with mammalian cell lines as the
consensus GRE is equal to the consensus progesterone and
androgen-responsive element (PRE and ARE) and thus can
also be activated by the PR and AR. This element is often
referred to as the hormone-responsive element (HRE). To
avoid potential cross talk in mammalian cell lines, lots of
efforts were made to construct specific GREs, PREs and
AREs [35]. However, up until now, such specific respon-
sive elements do not seem to exist, and it is doubtful
whether they will be found. So far, this resulted in cell lines
that are not specific and suffer from cross talk [36, 37]. In order
to fully exclude the cross talk, the latest AR, PR and GR-
CALUX tests are based on the human U2-OS bone cell line
that, just as yeast cells, expresses no endogenous ER, AR, PR
and GR [30, 34, 38]. Although less sensitive, yeast-based
assays were shown to be more robust and specific compared
with their mammalian analogues [5]. Here, a recombinant
yeast cell was constructed that expresses the hGRα and
yEGFP as a reporter protein in response to glucocorticoids.
Both the receptor construct as well as the reporter construct
were stably integrated into the yeast genome by the use of
yeast-integrating plasmids. High expression levels of the
hGRα were obtained by placing the cDNA of the hGRα
gene behind the strong constitutive yeast GPD promoter.
Transfected strains were checked with PCR and the
correct and specific functioning of this yeast glucocorti-
coid bioassay was studied by exposures to cortisol and
other related compounds; the outcomes were critically
compared with the specific U2-OS-based GR-CALUX
bioassay.
Stable transfection of the HRE2-CYC1-yEGFP-Ura reporter
yeast with the GPD-hGRα-His receptor construct
The Saccharomyces cerevisiae strain K20 (Ura-, His-, Leu-)
stably transformed with the p406-HRE2-CYC1-yEGFP-Ura
reporter construct was described previously [33]. This strain
was stably transformed with the p403-GPD-hGRα-His
receptor expression construct. Stable transformants, i.e.
with the receptor construct integrated in the yeast genome
at the chromosomal location of the Histidine gene via
homologous recombination, were checked with PCR con-
trols. Yeast chromosomal DNA of transformants was
isolated and three PCR controls were performed. Figure 1
shows the gel electrophoresis results of these PCR controls.
As expected, PCR I, II and III gave the specific 2,334-,
539- and 2,590-bp PCR products, demonstrating that the
yeast glucocorticoid biosensor contains the p403-GPD-
hGRα receptor expression vector stably integrated in the
yeast genome.
Dose–response curves obtained with the yeast
glucocorticoid bioassay
The dose–response curves for several natural and
synthetic (gluco)corticoids are shown in Fig. 2. Aldoste-
Fig. 1 PCR controls on yeast chromosomal DNA of p403-GPD-
hGRα receptor expression transformants. PCR I with primer set 1
gives a specific 2,334-bp product, PCR II with primer set 2 gives a
specific 539-bp product, and PCR III with primer set 3 gives a specific
2,590-bp PCR product
Fig. 2 Dose–response curves of several corticosteroids obtained in
the yeast glucocorticoid bioassay
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rone, betamethasone, budesonide, corticosterone, cortisol,
dexamethasone and prednisolone caused a dose-related
increase in the production of yEGFP, demonstrating that
these compounds are potent glucocorticoids. The bioassay
showed a limit of detection, i.e. showing responses above
the background signal plus three times the standard
deviation on the mean background signal, of 0.5 μM for
the most potent glucocorticoid budesonide with a dynamic
range from 0.5 to 10 μM and in general low standard
deviations (<5%).
Steroids representative for other hormone receptors,
like E2 for the ER and 5α-DHT for the AR, showed no
agonistic response, whilst P4, the natural ligand for the
PR, showed a small agonistic response. Table 1 shows
the calculated EC50 values, i.e. the concentration giving a
half-maximum response, and the relative corticoid potency
(RCP), defined as the ratio between the EC50 of
dexamethasone and the EC50 of the compound, for several
compounds. The yeast glucocorticoid bioassay showed
sensitivity towards all (gluco)corticoids tested, with the
following range of potencies: budesonide >> corticosterone >
dexamethasone > cortisol = betamethasone > prednisolone >
aldosterone. Cortisone and prednisone showed no response in
this bioassay.
Dose–response curves obtained with the U2-OS GR-CALUX
bioassay
Figure 3 shows the dose–response curves for several
natural and synthetic (gluco)corticoids as obtained in de
U2-OS cell-based GR-CALUX bioassay. Aldosterone,
betamethasone, corticosterone, cortisol, Dex and pred-
nisolone caused a dose-related increase in luciferase
activity, whilst cortisone and prednisone showed no
response. These outcomes are similar as obtained with
the yeast-based bioassay, although the ranking is slightly
different. The most distinct differences are obtained for
budesonide and fludrocortisone-21-acetate. Budesonide
was much more potent than Dex in the yeast bioassay, but
was equally potent in the GR-CALUX; fludrocortisone-
21-acetate was inactive in yeast, but is active in the GR-
CALUX. There is a great difference in the limit of
detection, which is at least three orders of magnitude
lower for the active glucocorticoids in the U2-OS cell-
based GR-CALUX. Table 1 shows the calculated EC50
and the RCP for several compounds as obtained in the
GR-CALUX.
Anti-glucocorticoid activity
The yeast glucocorticoid bioassay was further examined by
testing compounds that are known to display anti-
glucocorticoid activity. Figure 4 shows the agonistic and
antagonistic activities of the known partial GR agonist
mifepristone (RU486, which is mostly referred to as a PR
and GR antagonist) and three additional synthetic com-
pounds that were classified as GR antagonists by their
manufacturer due to their response in a mammalian cell-
based in vitro receptor-reporter gene assay. The antagonistic
properties were examined by co-exposure with a concen-
tration of dexamethasone that induced a half-maximal or
sub-maximal response, 150 or 500 μM, respectively.
Compound Yeast glucocorticoid assay GR-CALUX
EC50 (μM) RCP EC50 (nM) RCP
Dexamethasone 120 1.0 2.2 1.0
Budesonide 6 20 2.2 1.0
Betamethasone 149 0.8 11 0.2
Cortisol 123 1.0 37 0.06
Corticosterone 71 1.7 80 0.03
Cortisone Not active 0.0 Not active 0
Aldosterone 705 0.2 495 0.004
Fludrocortisone-21-acetate Not active 0.0 11 0.2
Prednisolone 643 0.2 12 0.2
Prednisone Not active 0.0 Not active 0
Triamcinolone Activea Active 19 0.1
Mifepristone 578 0.2 Not activeb 0
17β-Estradiol (E2) Not active 0.0 Not active 0
5α-Dihydrotestosterone Not active 0.0 Not active 0
Progesterone (P4) Activea Active Activea Active
Table 1 Calculated EC50 value
and RCP for several natural and
synthetic steroids as determined
in the yeast glucocorticoid and
U2-OS GR-CALUX bioassays
a Triamcinolone and progester-
one are slightly active in the
yeast bioassay, but their maxi-
mal responses are only about
10% and 6%, respectively, of the
maximal response as obtained
with dexamethasone; thus, it is
not appropriate to give an EC50
value or RCP. Progesterone is
also active in the GR-CALUX,
but its response is only about
4% of the maximal response as
obtained with dexamethasone
bMifepristone is not active as an
agonist in the GR-CALUX and
acts as a pure antagonist in this
assay
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Figure 4 shows that all compounds were active in yeast and
acted as agonists in the absence of dexamethasone. Figure 4
also shows that Org 34116 was not able to inhibit the response
caused by dexamethasone, and Org 34850 and Mifepristone
only slightly acted as GR antagonists at concentrations
between 10 and 100 μM and 50 and 500 μM, respectively.
Org 34517 clearly acted as a GR antagonist when co-exposed
with a concentration of dexamethasone that caused a near-
maximal response, i.e. 500 μM dexamethasone.
Figure 5 shows the glucocorticoid and anti-glucocorticoid
activities of mifepristone and Org 34517 as obtained in
the U2-OS-based GR-CALUX bioassay. The antagonistic
properties were examined by co-exposure with a con-
centration of dexamethasone that induced a half-maximal
or sub-maximal response, 1 or 10 nM, respectively. Both
compounds acted as pure GR antagonists in this
bioassay. Also, Org 34116 and 34850 acted as pure GR
antagonist in the U2-OS GR-CALUX, and there was no
difference in potency compared with Org 34517 (fully
identical dose–response curves for all three Org com-
pounds; data for the other two Org compounds are
therefore not shown).
Fig. 3 Dose–response curves of several corticosteroids obtained in
the U2-OS cell-based GR-CALUX bioassay
Fig. 4 GR agonistic and antagonistic characteristics of mifepristone (a), Org 34116 (b), Org 34517 (c) and Org 34850 (d) determined in the yeast
GR bioassay
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Glucocorticoid and anti-glucocorticoid activity
of environmental pollutants
Figure 6 shows the agonistic and antagonistic responses
of several PCBs as obtained in the yeast glucocorticoid
bioassay. The antagonistic properties were examined by
co-exposure with a concentration of budesonide that
induced a half-maximal or sub-maximal response, 5 or
5 μM, respectively. It shows that PCB47 and PCB100
only act as GR antagonists, and this antagonistic
response can only be envisaged when these compounds
are co-exposed with 5 μM budesonide. PCB92 acts as a
GR antagonist when co-exposed with either 5 or 50 μM
budesonide, but also has a slight agonistic effect on itself.
PCB101 is the most potent PCB tested; it displays an
agonistic effect that is almost comparable with that of
triamcinolone and progesterone and is also the strongest
GR antagonist, capable of inhibiting 50% of the response
caused by 50 μM budesonide and almost fully inhibiting
the response caused by 5 μM budesonide.
Discussion
In humans, the hGRα, in the absence of glucocorticoids, is
present in the cytoplasm and is bound to a complex of
proteins. This chaperone complex stabilizes the unliganded
hGRα in such a way that the LBD is able to bind
glucocorticoids. Heat shock protein 90 (HSP90) is one of
the most studied members of this chaperone complex
[39, 40]. The HSP90 chaperone protein is expressed in
most, if not all, cells and has an important role in the
protein folding process. This protein folding mechanism is
a highly conserved mechanism, and many organisms
Fig. 5 GR agonistic and antagonistic characteristics of mifepristone (a) and Org 34517 (b) determined in the U2-OS cell-based GR-CALUX
bioassay
Fig. 6 GR agonistic and antagonistic characteristics of several PCBs determined in the yeast GR bioassay: a Alone and in combination with
5 μM budesonide; b In combination with 50 μM budesonide
Cell bioassays for the detection of (gluco)corticosteroids 879
possess their own HSP90 homologs. For instance, in yeast,
like S. cerevisiae, there are no steroid hormone receptors
present, but genetic analyses revealed two HSP genes
encoding the similar isoforms HSP82 and HSC82 [41]. As
the transcription activation machinery in yeast is highly
conserved, the construction of yeast-based bioassays for
hormonal activities only requires the introduction of a
receptor construct and a reporter construct. Indeed, it has
been demonstrated that steroid hormone receptors, such as
hERα, hERβ, hAR and hPRB, exogenously expressed in S.
cerevisiae, can reach a hormone-binding conformation and,
in the presence of the proper ligand, activate a hormone-
inducible reporter gene. This study shows that also the
hGRα can reach an active state in yeast upon binding of a
ligand and is subsequently able to activate the transcription
machinery on the DNA from a hormone-responsive
element.
The new yeast glucocorticoid bioassay is less sensitive
than its mammalian analogue, e.g. EC50 for budesonide of
about 5 μM in yeast and 2 nM in the GR-CALUX. A lower
sensitivity was expected as also the yeast-based assays for
the detection of oestrogens, androgens and progestagins
have been shown to be less sensitive than their mammalian
analogues [29, 30, 33, 42–44]. However, the sensitivity of
this yeast glucocorticoid assay is relatively very low. This
becomes clear when the EC50 values for E2, P4, T and Dex
of respectively 0.5, 1, 50 and 100.000 nM in yeast-based
ER, PR, AR and GR bioassays are compared with their U2-
OS-based CALUX analogues, with EC50 values of respec-
tively 0.02, 0.6, 0.7 and 0.7 nM [29, 30, 33, 42–44]. The
relatively very low sensitivity of the yeast glucocorticoid
bioassay is most probably due to the absence of the
human HSP90 chaperone protein; the present data thus
suggest that HSP90 is more needed in yeast to obtain
optimal hGRα activity than it is needed to obtain fully
active ER, PR and AR.
On the other hand, the yeast GR bioassay is specific and
the outcomes with different compounds correlate well with
their known characteristics. Cortisol and corticosterone are
known active endogenous glucocorticoids, aldosterone is an
endogenous corticoid that is less active on the GR and more
active on the MR, and budesonide, dexamethasone,
betamethasone and prednisolone are known active synthetic
glucocorticoids. Budesonide, dexamethasone and predniso-
lone are known to be relatively potent, whilst betametha-
sone is known to be moderately potent. Although
budesonide is relatively very potent in the yeast glucocorticoid
bioassay, the potency ranking of these active compounds is as
expected. Moreover, the inactivity of cortisone, prednisone
and fludrocortisone-21-acetate in the yeast glucocorticoid
bioassay is also as expected. Corticosterone is an active
intermediate in the synthesis of both cortisol and aldosterone,
but cortisone is the inactive metabolite of cortisol that is
formed by 11β-steroid dehydrogenase in peripheral tissues.
Prednisone is a synthetic prodrug that is converted by the liver
into the active drug prednisolone, and fludrocortisone-21-
acetate is a synthetic drug that is mainly known as a
mineralocorticoid receptor agonist. Regarding the specificity,
both assays showed a small response when cells were exposed
to progesterone. This small GR-mediated corticoid activity of
progesterone is as expected as progesterone was already
classified as a partial glucocorticoid agonist before [45].
However, the activity of fludrocortisone-21-acetate in the
U2OS-based GR-CALUX was unexpected as cortisone was
inactive in this mammalian cell assay. Possibly, the human
bone cell is specifically able to convert fludrocortisone-21-
acetate into a cortisol analogue and displays esterase activity,
or perhaps the U2-OS cells express the MR and thus suffer
from cross talk [38].
Regarding the antagonistic characteristics of the com-
pounds tested, only Org 34517 was able to demonstrate
clear GR antagonistic properties in yeast and mifepristone;
the three Org compounds mainly acted as GR agonists in
the yeast bioassay, whilst all four compounds acted as pure
GR antagonists in the U2-OS GR-CALUX. However,
mifepristone is a partial PR and GR agonist. For its PR
antagonist properties, mifepristone was mainly used as an
arbotifacient in the first 2 months of pregnancy, but
mifepristone is also known to suppress the GR levels in
the human decidua and placenta; the latter might be part of
the mechanism of mifepristone in causing abortion too [46].
Thus, the anti-glucocorticoid in vivo effect of mifepristone
is at least partly caused by suppressing the GR levels
instead of directly acting as a GR antagonist. Moreover, the
outcome as observed in the yeast assay, i.e. mifepristone
acting as a GR agonist, correlates well with the observation
of Zhang et al. [47] showing that mifepristone acts as a GR
agonist in monkey COS-7 and mouse E8.2.A3 cells with
high GR levels, most probably similar as in yeast, where
the GR is strongly and continuously expressed. In addition,
mifepristone was also classified as an AR agonist and AR
antagonist [48]. Thus, this compound displays several
activities on several nuclear receptors and its response is
cell type-specific; the latter might be related to GR levels.
In general, mammalian cell-based assays for nuclear
receptors are more sensitive than yeast-based assays, but
mammalian cells need serum to grow, and as serum
contains small amounts of steroids and other growth
factors, the exposure of these cells to compounds and
sample extracts has to be performed in media with stripped
serum. Moreover, the measurement of the fluorescence
(yEGFP) can be followed as a function of incubation time
and is easier, quicker and cheaper than the measurement of
the β-galactosidase or luciferase activity, which requires
cell wall disruption and/or the addition of expensive
substrates. In addition, it has been demonstrated that S.
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cerevisiae contains none of the enzymes activities in the
steroidogenesis, e.g. aromatase, 5α-reductase, 3β-HSD or
17β-HSD, which makes yeast-based assays very specific as
differences in metabolism in human cell lines have led to
different outcomes [5]. However, despite the differences,
different assay types are complementary and needed
together to be able to elicit the mechanism of actions of
compounds and their metabolites [5].
In summary, although the new yeast glucocorticoid
bioassay is relatively insensitive and might be less suited
for sample analysis requiring a low sensitivity, it is specific.
Just as the U2-OS GR-CALUX, it is able to detect the
known agonistic properties of natural and synthetic (gluco)
corticoids, whilst steroids representative for other hormone
receptors showed no response. The GR yeast bioassay is
thus suited to test the characteristics of pure compounds;
this was further demonstrated with several environmental
PCB pollutants that are known to possess endocrine-
disrupting potencies as these PCBs also effected the
activation of the GR in the yeast bioassay, including GR
antagonism. PCB101, together with its 3MeSO2 metabolite,
one of the most abundant PCBs present in humans and
wildlife, turned out to be rather potent. It displayed an
agonistic effect that was almost comparable with that of the
partial GR agonist progesterone. PCB101 was also a strong
GR antagonist, almost capable of fully inhibiting the
response caused by 5 μM budesonide. The physiologic
relevance of the latter should be explored further.
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